BlackRock Health Sciences Trust — Cyborg Score 7/10

Strategic Profile

The Trust pursues its goal primarily by investing in a portfolio of equity securities and by employing a strategy of writing (selling) call and put options. Led by portfolio manager Erin Xie, PhD, Managing Director and head of the Health Sciences team at BlackRock, with over two decades of experience including prior management of the State Street Health Sciences Fund.

Cyborg Score Rationale

Established closed-end fund with experienced management team and diversified health sciences exposure. Strong option writing strategy for income generation, though subject to market volatility in healthcare sector. Limited current 2026 data available for deeper performance assessment.

Top Insights

• Active healthcare sector focus with managed portfolio of pharma, biotech, life sciences, healthcare equipment/services, and semiconductors
• Uses option writing strategy to enhance yields alongside equity capital appreciation objective
• Benchmarked against Russell 3000 Healthcare Index with experienced doctoral-level portfolio management
• Low daily volatility profile with established liquidity supporting retail and institutional investors

Named Competitors

• IShares Global Healthcare ETF — Broad global healthcare equity exposure through ETF structure
• Invesco Healthcare ETF — Healthcare sector focused ETF alternative to closed-end funds
• Vanguard Healthcare ETF — Large-cap healthcare index exposure with lower cost structure

Recent Developments

• (April 2026) Overall Morningstar Rating assessed relative to 7 Health Funds peer group
• (February 2026) Stock trading around $42.15 with positive short-term technical signals
• (January 2026) Mixed technical signals with both buy signals from moving averages and some sell signals from pivot points

Open the full interactive BlackRock Health Sciences Trust report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.